ADAM22 — ADAM Metallopeptidase Domain 22

ADAM22 — ADAM Metallopeptidase Domain 22

Introduction

ADAM22 (A Disintegrin And Metalloproteinase domain 22) is a member of the ADAM family of transmembrane proteins that plays a critical role in synaptic function and neurological disease. Unlike many ADAM family members, ADAM22 is catalytically inactive, functioning primarily as a cell adhesion molecule rather than a protease. This unique characteristic makes it a crucial mediator of synaptic architecture and neuronal signaling through its role as the primary receptor for the leucine-rich glioma inactivated 1 (LGI1) protein[@fukata2006].

The gene encoding ADAM22 is located on chromosome 7q21.2 and is expressed predominantly in the central nervous system, particularly in brain regions essential for cognitive function and motor control. The protein localizes to postsynaptic membranes, where it forms trans-synaptic complexes with presynaptic proteins to regulate neurotransmitter release and synaptic plasticity. Mutations in ADAM22 have been implicated in genetic epilepsy, Alzheimer's disease, and autism spectrum disorder, highlighting its importance in maintaining normal neurological function[@schulte2016].

Research over the past two decades has established ADAM22 as a critical node in synaptic signaling networks, with effects on AMPA receptor trafficking, neuronal excitability, and myelination. This comprehensive review examines the molecular biology of ADAM22, its interactions with LGI1 and other proteins, and its involvement in neurodegenerative and neurodevelopmental disorders.

ADAM22 — ADAM Metallopeptidase Domain 22

Introduction

ADAM22 (A Disintegrin And Metalloproteinase domain 22) is a member of the ADAM family of transmembrane proteins that plays a critical role in synaptic function and neurological disease. Unlike many ADAM family members, ADAM22 is catalytically inactive, functioning primarily as a cell adhesion molecule rather than a protease. This unique characteristic makes it a crucial mediator of synaptic architecture and neuronal signaling through its role as the primary receptor for the leucine-rich glioma inactivated 1 (LGI1) protein[@fukata2006].

The gene encoding ADAM22 is located on chromosome 7q21.2 and is expressed predominantly in the central nervous system, particularly in brain regions essential for cognitive function and motor control. The protein localizes to postsynaptic membranes, where it forms trans-synaptic complexes with presynaptic proteins to regulate neurotransmitter release and synaptic plasticity. Mutations in ADAM22 have been implicated in genetic epilepsy, Alzheimer's disease, and autism spectrum disorder, highlighting its importance in maintaining normal neurological function[@schulte2016].

Research over the past two decades has established ADAM22 as a critical node in synaptic signaling networks, with effects on AMPA receptor trafficking, neuronal excitability, and myelination. This comprehensive review examines the molecular biology of ADAM22, its interactions with LGI1 and other proteins, and its involvement in neurodegenerative and neurodevelopmental disorders.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADAM Metallopeptidase Domain 22</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADAM22</td></tr>
<tr><td><strong>Full Name</strong></td><td>ADAM metallopeptidase domain 22</td></tr>
<tr><td><strong>Chromosome</strong></td><td>7q21.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5365](https://www.ncbi.nlm.nih.gov/gene/5365)</td></tr>
<tr><td><strong>OMIM</strong></td><td>605283</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000010704</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9P121](https://www.uniprot.org/uniprot/Q9P121)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Epilepsy, Alzheimer's Disease, Autism Spectrum Disorder</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The ADAM22 gene spans approximately 25 kilobases and consists of 24 exons encoding a protein of 834 amino acids. The genomic structure follows the conserved pattern of ADAM family genes, with a prodomain, metalloproteinase domain, disintegrin domain, cysteine-rich region, EGF-like domain, transmembrane domain, and cytoplasmic tail. However, critical mutations in the zinc-binding motif (HEXGHNLG) of the metalloproteinase domain render ADAM22 catalytically inactive[@sagane2008].

Protein Domains

The ADAM22 protein contains several distinct domains that mediate its functions:

The cytoplasmic tail of ADAM22 is particularly important, terminating in the sequence EVKV, which binds to PDZ domain-containing proteins including MAGUK family members. This interaction is essential for clustering ADAM22 at synaptic membranes and coupling it to intracellular signaling pathways[@owu2013].

Biological Functions

LGI1 Receptor Function

The primary known function of ADAM22 is as the postsynaptic receptor for LGI1. LGI1 is a secreted protein that was originally identified as a tumor suppressor in glioma. The LGI1-ADAM22 complex forms trans-synaptic bridges that are essential for proper synaptic function[@yamagata2018].

LGI1 binds to ADAM22 through its leucine-rich repeat (LRR) domain, interacting specifically with the cysteine-rich region and disintegrin domain of ADAM22. This binding is of high affinity (Kd ~10-100 nM) and is essential for the localization and function of both proteins at synapses. The LGI1-ADAM22 complex interacts with presynaptic ADAM23 to form trans-synaptic bridges that regulate neurotransmitter release[@fukata2006].

AMPA Receptor Trafficking

ADAM22 plays a critical role in the trafficking and localization of AMPA-type glutamate receptors at postsynaptic membranes. Through its interaction with the LGI1-ADAM22 complex and associated MAGUK scaffold proteins, ADAM22 recruits and stabilizes AMPA receptors at excitatory synapses. Loss of ADAM22 function leads to reduced AMPA receptor density and impaired synaptic transmission[@choi2021].

The mechanism involves direct interaction between ADAM22 and the AMPA receptor subunits GluA1-4, particularly through the stargazin-like transmembrane AMPA receptor regulatory proteins (TARPs). This interaction is dependent on the PDZ-binding motif in the ADAM22 cytoplasmic tail and the presence of LGI1[@liu2021].

Regulation of Neuronal Excitability

By modulating synaptic transmission through AMPA receptor trafficking, ADAM22 indirectly regulates neuronal excitability. Studies in knockout mice demonstrate that ADAM22 deficiency leads to increased neuronal excitability and spontaneous seizures. This effect is mediated primarily through impaired inhibitory synaptic function and reduced postsynaptic responses to excitatory neurotransmitters[@lee2020].

Oligodendrocyte Function and Myelination

ADAM22 is expressed not only in neurons but also in oligodendrocytes and their precursors. In oligodendrocytes, ADAM22 participates in myelination processes through mechanisms that are still being characterized. ADAM22 deficiency leads to hypomyelination and axonal degeneration in white matter tracts, highlighting its importance in glial cells as well as neurons[@zhou2022].

Expression Pattern

Brain Regions

ADAM22 exhibits high expression in regions of the central nervous system:

• Cerebral Cortex: Particularly layer V pyramidal neurons
• Hippocampus: CA1 and CA3 regions, dentate gyrus granule cells
• Cerebellum: Purkinje cells and deep cerebellar nuclei
• Brainstem: Sensory and motor nuclei
• Spinal Cord: Motor neurons and interneurons

Cellular Localization

At the subcellular level, ADAM22 localizes primarily to postsynaptic densities (PSDs) of excitatory synapses. It colocalizes with postsynaptic marker proteins including PSD-95, NMDA receptor subunits, and AMPA receptor subunits. The protein is anchored to the postsynaptic membrane through its transmembrane domain, with its extracellular domain facing the synaptic cleft to interact with presynaptic ligands.

Disease Associations

Genetic Epilepsy

ADAM22 mutations are associated with autosomal dominant lateral temporal lobe epilepsy (ADLTE). These mutations typically result in haploinsufficiency, leading to reduced ADAM22 protein levels or function at synapses. Patients present with focal seizures originating from the lateral temporal lobe, often with auditory features[@schulte2016].

The mechanism involves impaired LGI1 binding and consequent disruption of synaptic signaling. Reduced ADAM22 function leads to decreased AMPA receptor trafficking and altered synaptic plasticity. Notably, mutations in both ADAM22 and LGI1 can cause similar epilepsy phenotypes, highlighting the importance of the LGI1-ADAM22 axis in seizure suppression[@yang2024].

Alzheimer's Disease

Multiple lines of evidence suggest a role for ADAM22 in Alzheimer's disease pathophysiology:

• Amyloid Processing: ADAM22 expression is altered in AD brain tissue; the protein may influence APP processing and amyloid-beta generation
• Synaptic Dysfunction: ADAM22 levels are reduced in AD brains, correlating with cognitive decline
• Tau Pathology: The LGI1-ADAM22 pathway may intersect with tau phosphorylation and spreading
• Neuroinflammation: ADAM22 expression is modulated by inflammatory cytokines in AD

Autism Spectrum Disorder

Given the critical role of ADAM22 in synaptic function, it is not surprising that ADAM22 variants have been implicated in autism spectrum disorder (ASD). Rare missense mutations in ADAM22 have been identified in patients with ASD, and these mutations often show dominant-negative effects on synaptic function. The phenotype includes social deficits, communication difficulties, and repetitive behaviors consistent with impaired synaptic connectivity[@peng2022].

Additional Neurological Conditions

• Ataxia: ADAM22 deficiency causes cerebellar dysfunction and motor coordination deficits[@chen2020]
• Sleep Disorders: The LGI1-ADAM22 pathway influences circadian rhythms and sleep architecture[@thompson2023]
• Traumatic Brain Injury: ADAM22 may play roles in neural repair and recovery after injury[@su2024]

Therapeutic Implications

Epilepsy Treatment

Understanding the LGI1-ADAM22 axis has provided new therapeutic targets for epilepsy:

• LGI1 Mimetics: Small molecules that activate ADAM22 signaling
• ADAM22 Stabilizers: Compounds that enhance ADAM22 membrane localization
• Gene Therapy: Viral vector delivery of functional ADAM22

Alzheimer's Disease

ADAM22-based therapeutic strategies for AD include:

• Protein Replacement: Recombinant LGI1 or ADAM22 delivery
• Small Molecule Activators: Compounds that enhance the LGI1-ADAM22 interaction
• Gene Therapy: AAV-mediated ADAM22 expression

Neurodevelopmental Disorders

For ASD and related conditions, strategies include:

• Early Intervention: Targeting ADAM22 function during critical developmental periods
• Corrective Approaches: Enhancing synaptic plasticity through ADAM22 pathways
• Combination Therapies: ADAM22 modulation with other targeted interventions

Molecular Signaling Pathways

Presynaptic Modulation

The LGI1-ADAM22 complex influences presynaptic function through retrograde signaling. Binding of LGI1 to ADAM22 triggers presynaptic changes that regulate neurotransmitter release. This involves modulation of voltage-gated calcium channels and synaptic vesicle release machinery[@owu2013].

Postsynaptic Signaling

At the postsynaptic density, ADAM22 activates several signaling cascades:

These pathways integrate signals from ADAM22 to regulate synaptic strength, dendritic spine morphology, and neuronal survival[@kong2023].

Interactions with Other Proteins

ADAM22 interacts with numerous proteins beyond LGI1:

• ADAM23: Presynaptic partner in trans-synaptic complexes
• MAGUK Proteins: PSD-95, SAP97, and other PDZ domain proteins
• AMPA Receptor Subunits: GluA1-4 through TARPs
• Voltage-Gated Potassium Channels: Regulation of neuronal excitability
• Integrins: Cell adhesion and migration functions

Animal Models

Knockout Mouse Studies

ADAM22 knockout mice exhibit:

• Severe Spontaneous Seizures: Beginning at postnatal day 12-14
• Premature Death: Most die within 3 weeks of birth
• Impaired Synaptic Transmission: Reduced evoked and spontaneous excitatory postsynaptic currents
• Abnormal Myelination: Hypomyelination in white matter tracts
• Ataxia: Motor coordination deficits

Conditional Knockouts

Tissue-specific knockouts have revealed:

• Neuron-Specific Deletion: Causes seizures and synaptic dysfunction
• Oligodendrocyte-Specific Deletion: Causes hypomyelinvation without seizures
• Astrocyte-Specific Deletion: Shows minimal phenotypes

Future Research Directions

Structural Studies

High-resolution structural studies of the LGI1-ADAM22 complex are needed to:

• Define the precise binding interface
• Guide small molecule drug design
• Understand disease-causing mutations

Biomarkers

Development of biomarkers for ADAM22-related conditions includes:

• Circulating LGI1/ADAM22: Levels in cerebrospinal fluid as disease markers
• Genetic Testing: Population screening for ADAM22 variants
• Functional Assays: Patient-derived neuron models for drug testing

Clinical Translation

Translational priorities include:

• Developing brain-penetrant ADAM22 modulators
• Gene therapy approaches for ADAM22 deficiency
• Biomarker development for patient stratification
• Clinical trials for ADAM22-targeted interventions

Mechanism Map

See Also

• [LGI1](/genes/lgi1) — Ligand for ADAM22
• [ADAM23](/genes/adam23) — Presynaptic partner
• [ADAM10](/genes/adam10) — Alpha-Secretase
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Epilepsy](/diseases/epilepsy)
• [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)
• [AMPA Receptors](/entities/ampa-receptors)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
• [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References